Gossamer Bio announces $250m in funding to advance seralutinib
The proceeds will help advance seralutinib's clinical development and potential commercialisation.
Drug Development
WellSpan and Johns Hopkins renew partnership for advanced cancer care access
Charles River and MVC to develop enterovirus vaccine
FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy
SandboxAQ introduces AQPotency for virtual drug screening
Andelyn Biosciences to develop GM2 gangliosidosis therapy
BeOne Medicines and partners renew Brukinsa access programme for CLL
Faeth’s PIKTOR plus paclitaxel combo gains FDA fast track status
